Envoy Medical vs Nexalin Technology
COCH and NXL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COCH and NXL compare
Envoy Medical is the larger company, worth 16 times as much as Nexalin Technology ($534M against $34.4M).
Nexalin Technology grew revenue faster over the last twelve months (24.2% versus −6.8% for Envoy Medical).
Nexalin Technology keeps more of each dollar of sales as profit, with a net margin of −4139% compared with −11305% at Envoy Medical.
Nexalin Technology scores higher on the StockData Score (7 against 5 for Envoy Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COCH | NXL |
|---|---|---|
| Size and price | ||
| Market cap | $534M | $34.4M |
| Share price | $6.92 | $1.56 |
| Change, 1 year | 942% | −95.6% |
| Change, 5 years | −92.9% | – |
| Beta (5Y) | 1.36 | 2.73 |
| Employees | 43 | 8 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2581× | 158× (better) |
| P/B | 162× | 22.6× (better) |
| Growth | ||
| Revenue growth (TTM) | −6.8% | 24.2% (better) |
| Profitability | ||
| Gross margin | −386% | 86.2% (better) |
| Operating margin | −11411% | −4203% (better) |
| Net margin | −11305% | −4139% (better) |
| Return on equity | – | −240% |
| Return on invested capital | – | −2105% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.73 (better) | 1.25 |
| Altman Z-score | −6.04 (better) | −41.21 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −5.7% | – |
| Shareholder yield | −5.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 39.7% | 0.13% |
| Held by insiders | – | 22.3% |
| Insider net buying, 12 months | $8.2M | – |
| Short interest, % of float | – | 0.07% |
Go deeper
- COCH stock overview
- COCH income statement
- COCH valuation and score
- NXL stock overview
- NXL income statement
- NXL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.